Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06588205 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Exploring the Clinical Impact of MYC Aberrations and Their Relationship With Microenvironment in Diffuse Large B Cell Lymphoma and High-Grade B Cell Lymphoma

Study acronym: FIL_MIMYC
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Site details revised at 6 of 20 sitesv6
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Dec 2024 to May 5, 2025
    • Study sites: 19 to 20
    v5
  3. Study title revisedv4
  4. Study sites: 20 to 19v3
  5. Study sites: 19 to 20
    • Secondary endpoints: details revised at 3 of 6 entries
    v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a observational, retrospective and prospective study designed to assess the potential correlations between MYC alterations, lymphoma mutational landscape and functional immune contextures in Diffuse Large B-cell Lymphoma or High-Grade B-cell Lymphoma
Trial Details
NCT Number NCT06588205
Lead Sponsor Fondazione Italiana Linfomi - ETS
Conditions
(from sponsor)		 Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
Related terms Lymphoma, Large B-Cell, Diffuse
Enrollment 200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov